Core Portfolio & Strategy - Park Hotels & Resorts focuses on upper-upscale and luxury full-service hotels in premier urban and resort destinations, affiliated with dominant global brands[4] - The company's core portfolio includes 20 consolidated hotels and 1 unconsolidated hotel, totaling 16,000 rooms[13] - Park plans to dispose of non-core hotels to enhance growth and quality, with estimated proceeds of $560 million to $600 million expected from non-core hotel sales[55, 61] - The strategic plan involves disposing of remaining non-core hotels over the next 12+ months to materially enhance growth and quality[46] Financial Performance & Valuation - Park Hotels & Resorts is trading at a 47% discount to the consensus estimate of NAV (Net Asset Value)[14] - The implied market value of the portfolio is $270,000 per key, while the replacement cost for the core portfolio is approximately $1 million per key[14] - The company offers an attractive dividend yield of 9%[14] - The company has over $2 billion of liquidity, including $1 billion available under the revolving credit facility and an unsecured $800 million delayed-draw term loan[15] ROI & Growth Potential - Park Hotels & Resorts has a robust ROI pipeline with $1 billion of potential opportunities, with past projects generating 20%+ average IRR (Internal Rate of Return)[15] - Since 2018, $1.4 billion of capital will have been invested in the core portfolio through 2025, or $87,000 per key[14] - The company anticipates $100 million+ Adjusted EBITDA growth potential as core markets recover and ROI projects stabilize[14]

Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 in Recurrent Genital Herpes December 8, 2025 Nasdaq: ASMB ©2025 ASSEMBLY BIOSCIENCES, INC. Cautionary Note Regarding Forward-Looking Statements The information in this presentation contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio's ability to re ...

Company Overview - Lineage operates 488 warehouses with 3.1 billion cubic feet of space and approximately 86 million square feet across 19 countries[10] - The company's annual operating expense is $2.4 billion, including $1.4 billion in labor and $0.2 billion in energy[10] - Lineage's 2024 Adjusted EBITDA was $1.3 billion[10] Market Dynamics - The estimated US new PRW (Public Refrigerated Warehouse) supply from 2021-2025 is projected to increase by 14.5%[15] - Estimated demand is at 5%, resulting in an excess capacity of 9.5%[15] - Lineage's total physical occupancy is at 78%[15] LinOS and Technology - Lineage expects LinOS to deliver $180 million of NOI (Net Operating Income) upside by 2030[64] - The company plans to implement LinOS at over 250 warehouses by 2029[55] - Initial High Reach Operations (HRO) pilots have driven a +30% average unit per hour improvement[98] Labor and Productivity - Team member turnover has decreased from 56% in 2022 to 25% YTD in 2025[34] - LinOS implementation has shown a 5% average improvement in total labor/throughput pallet[98] Investment and Returns - The total cumulative project investment in LinOS is projected to be approximately $450 million[113] - The base case estimate for annualized savings in 3-5 years is $110 million, with a 24% ROIC (Return on Invested Capital)[113]

Acquisition - Phreesia acquired AccessOne for $160 million in cash, funded by a mix of cash and debt [11, 12] - The acquisition extends Phreesia's reach into provider financing, addressing a $74 billion market [13, 15] - AccessOne's results are not included in the Q3 FY2026 presentation [6] Financial Performance - Total revenue for Q3 FY2026 was $120 million, a 13% year-over-year increase [19] - Adjusted EBITDA for Q3 FY2026 was $29 million, a 198% year-over-year increase [19] - Total revenue per AHSC for Q3 FY2026 was $26600, a 6% year-over-year increase [19] Outlook - FY2026 total revenue is projected to be between $479 million and $481 million, with Adjusted EBITDA between $99 million and $101 million [51] - The company anticipates approximately 4515 AHSCs for FY2026 [51] - FY2027 total revenue is projected to be between $545 million and $559 million, with Adjusted EBITDA between $125 million and $135 million [53, 54]

Company Overview - Ooma is a multi-tenant SaaS platform for telephony, messaging, video, and more, serving over 1.2 million core users[8] - The company's annual exit recurring revenue (AERR) is $243 million, with a recurring gross profit margin of 72%[8] - Ooma boasts a 99% net dollar subscription retention rate (NDR)[8] Financial Performance - Ooma's revenue is $264 million, with adjusted EBITDA of $29 million[8] - The company targets a long-term subscription & services gross margin of 75%-78%[62] - Ooma's target model includes a long-term adjusted EBITDA margin of 20%-25% of revenue[62] Market Opportunity - The worldwide hosted voice/UC public cloud (UCaaS) market is projected to grow at a CAGR of 7% from $23 billion in 2023 to $32 billion in 2028[28] - The North American business market has 57 million business lines[28] - Ooma addresses a >10 million line U S market opportunity in POTS (copper line) replacement[40]

TERN-701 Efficacy and Safety - TERN-701 demonstrated a 64% Major Molecular Response (MMR) achievement rate at 24 weeks across all doses in non-T315I CP-CML patients (N=38)[20, 26] - At doses ≥320 mg QD, TERN-701 achieved a 75% MMR rate and a 36% Deep Molecular Response (DMR) rate at 24 weeks[18, 26, 75] - The majority of Treatment-Emergent Adverse Events (TEAEs) were low grade, with Grade 3 AEs less than 10%[18, 26] - No Dose Limiting Toxicities (DLTs) were observed, and the Maximum Tolerated Dose (MTD) was not identified[26, 37] - The study observed no pancreatic toxicity or clinically significant changes in blood pressure[18, 26] Patient Population and Treatment - The CARDINAL study enrolled a predominantly 3L+ refractory CML population (N=63 as of September 13, 2025)[24] - 38% of patients had prior asciminib treatment, with 75% of those discontinuing due to lack of efficacy[26, 33] - 87% of patients remained on treatment with a median treatment duration of 6.1 months[35] Competitive Landscape and Future Development - Asciminib NBRx share in 2L is 52% and in 3L+ is 53%[7] - Asciminib NBRx share of front-line is 22%[7] - TERN-701 is positioned to potentially capture new patients and switch from both Asciminib and Active Site TKIs[103] - Multiple catalysts are planned in 2026, including expanded CARDINAL data, pivotal dose selection, and alignment with regulators for pivotal studies[99, 106]

VIEW SHARE Netflix and Warner Bros. combined will have 9.2% TV viewshare in the U.S. Nielsen Share of U.S. TV Time By Distributor 1 October 2025 October 2025 Pro Forma YouTube The Walt Disney Company Netflix & Warner Bros. NBCUniversal FOX Paramount Discovery Global 12.9% 11.4% 9.2% 8.6% 4.4% 8.4% 8.2% 1.2% HBO / HBO Max YouTube 12.9% The Walt Disney Company NBCUniversal FOX Paramount Netflix 11.4% 8.6% 8.4% 8.0% 5.6% 8.2% Warner Bros. Discovery 1.2% HBO / HBO Max ...

NYSE-A:CTGO TSX-V:DV | NYSE-A:DVS MERGER TO CREATE A NEW NORTH AMERICAN HIGH-GRADE, MID-TIER SILVER & GOLD PRODUCER AND DEVELOPER I N V E S T O R P R E S E N TAT I O N D E C E M B E R 2 0 2 5 W W W . C O N T A N G O O R E . C O M W W W . D O L L Y V A R D E N S I L V E R . C O M DISCLAIMER LEGAL DISCLAIMER The information contained in this presentation furnished by or on behalf of Dolly Varden Silver Corporation ("Dolly Varden") or Contango ORE, Inc. ("Contango") has been prepared in respect of the proposed ...

Ziftomenib + Ven/Aza in Newly Diagnosed NPM1-m AML - In newly diagnosed NPM1-m AML patients, the combination of ziftomenib 600 mg QD with Ven/Aza resulted in a composite complete remission (CRc) rate of 86% (32/37), with a complete remission (CR) rate of 73% (27/37)[35] - Among CRc responders in newly diagnosed NPM1-m AML, 68% (17/25) achieved MRD negativity at a threshold of ≤01% and 44% (11/25) at a threshold of ≤001%[36] - In newly diagnosed NPM1-m AML, 68% (27/40) of patients remained alive and continued on study after a median follow-up of 261 weeks[40] Ziftomenib + Ven/Aza in R/R NPM1-m or KMT2A-r AML - In R/R NPM1-m AML patients, the combination of ziftomenib 600 mg with Ven/Aza resulted in an overall response rate (ORR) of 65% (31/48) and a CRc rate of 48% (23/48)[57] - In R/R KMT2A-r AML patients, the combination of ziftomenib 600 mg with Ven/Aza resulted in an ORR of 41% (13/32) and a CRc rate of 28% (9/32)[57] - Among R/R NPM1-m AML patients without prior venetoclax exposure, the CRc rate was 70% (16/23) and the ORR was 83% (19/23)[58] - Among R/R KMT2A-r AML patients without prior venetoclax exposure, the CRc rate was 60% (6/10) and the ORR was 70% (7/10)[58] - For R/R NPM1-m AML, the median duration of CRc was 399 weeks after a median follow-up of 274 weeks[61] - For R/R KMT2A-r AML, the median duration of CRc was 124 weeks after a median follow-up of 169 weeks[64]

Paramount's $30 all-cash offer provides greater value and certainty to WBD shareholders December 8, 2025 Disclaimer This presentation is provided for informational purposes only and for no other purpose. Certain information contained herein has been obtained from published sources prepared by third parties that Paramount Skydance Corporation ("Paramount") believes to be reliable. Moreover, certain information in this presentation is based on assumptions, estimates and other factors that were available to Pa ...